Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Gyroscope

14.02.2020

Gyroscope Therapeutics strengthens leadership team ahead of next stage of company growth

Gyroscope Therapeutics, a company developing gene therapies and surgical delivery systems for retinal diseases, announces the strengthening of its leadership team with the hiring of Dr. Nadia Waheed from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO) and the promotion of Dr. Jane Hughes, formerly VP Translational Research, to Chief Scientific Officer (CSO).
Gyroscope
Freeline
SwanBio

23.10.2019

Building Syncona’s Gene Therapy Platform

Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt explain how Syncona has built a globally leading platform of unpartnered gene therapy assets.
Gyroscope
SwanBio
Freeline

23.10.2019

An Introduction to Gene Therapy

Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt, provide an introduction to gene therapy, a field where Syncona has developed deep domain expertise and built a strategic platform.
Gyroscope

19.02.2019

Gyroscope Therapeutics announces first patient dosed in Phase I/II study in dry AMD

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, announces that its portfolio company, Gyroscope Therapeutics (Gyroscope), an ophthalmology company developing genetically defined therapies for retinal diseases such as age-related macular degeneration (AMD), has commenced dosing in a Phase I/II trial in dry AMD.
Gyroscope

14.11.2018

Gyroscope Therapeutics led consortium secures INNOVATE UK funding to develop a suspension platform for cost effective manufacture of novel AAV gene therapies

Gyroscope Therapeutics (Gyroscope) and Freeline Therapeutics (Freeline) are partnering with two research organisations, NHSBT's Clinical Biotechnology Centre (CBC) and the Centre for Process Innovation (CPI), to develop and design a manufacturing platform to produce novel (adeno-associated virus) AAV gene therapies. The consortium has been awarded £1.1m funding by Innovate UK over a period of 2 years.
Gyroscope

20.09.2017

Gyroscope Therapeutics appoints Dr Soraya Bekkali as Chief Executive Officer

Gyroscope Therapeutics, an ophthalmology company developing genetically defined therapies for retinal diseases such as age related macular degeneration (AMD), is pleased to announce the appointment of Dr Soraya Bekkali as Chief Executive Officer and Director of its Board.